Award

National Institute of Allergy and Infectious Diseases 5R01AI170189-05

Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection

Recipient

MASSACHUSETTS GENERAL HOSPITAL

Award Amount

$471,626.00

Ceiling

$471,626.00

Awarded

April 02, 2026

Identifier

5R01AI170189-05

The award supports the development of an allogeneic CAR T cell therapy to achieve a functional cure for HIV by enhancing T cell persistence and antiviral efficacy, funded by the National Institute of Allergy and Infectious Diseases.

Description

This project aims to develop an allogeneic CAR T cell therapy targeting HIV, leveraging expertise in CAR T cell biology, base editing, and humanized mouse models. The project includes specific aims to determine genetic modifications for T cell persistence, identify characteristics associated with efficacy, and compare in vivo efficacy of allogeneic versus autologous T cells. The award is funded by the NIH/NIAID with a total amount of $471,626 for fiscal year 2026.

View original record